Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02254239 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

10

Enrollment

OTHER

Sponsor class

Stopped funding withdrawal

Conditions

Recurrent Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
DRUG: Everolimus
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study

Sponsor

Mayo Clinic

Collaborators

[object Object]